Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to provide high-quality, innovative, and accessible vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a robust pipeline of 17 vaccines preventing 12 diseases, including the world’s initial vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) approved in over 10 countries and granted EUL by the WHO, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia approved by NMPA in China. Recently, our pioneering inhaled COVID-19 vaccine Convidecia Air has been approved as booster dose in China. Additional information can be found online at www.cansinotech.com.